Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Salmeterol/fluticasone combination in the treatment of COPD Chung KFInt J Chron Obstruct Pulmon Dis 2006[]; 1 (3): 235-42Clinical trials of a combination therapy of an inhaled corticosteroid, fluticasone propionate (FP), with a long-acting beta2-agonist, salmeterol (Sal), have demonstrated a greater improvement in lung function and in quality of life measures after the combination compared with either component of alone. In a subanalysis of the data of the TRISTAN study, Sal/FP reduced exacerbation rates in COPD patients with a baseline FEV1 < 50% of predicted. A combination therapy of budesonide and formoterol improved quality of life and FEV1, and reduced exacerbations better than either component alone. In studies of FP or of Sal/FP in COPD, there was a reduction in all-cause mortality by 25% relative to placebo. Sal/FP has anti-inflammatory effects in COPD airways. FP inhibits markers of systemic inflammation, and it is not known whether Sal/FP has an advantage over FP alone. While long-acting beta2-agonists such as Sal can be recommended for treatment of moderate COPD, addition of inhaled steroid therapy such as FP should be considered in more severe disease.|Adrenergic beta-Agonists/administration & dosage/pharmacology/*therapeutic use[MESH]|Albuterol/administration & dosage/*analogs & derivatives/pharmacology/therapeutic use[MESH]|Androstadienes/administration & dosage/pharmacology/*therapeutic use[MESH]|Bronchodilator Agents/administration & dosage/pharmacology/*therapeutic use[MESH]|Clinical Trials as Topic[MESH]|Drug Therapy, Combination[MESH]|Fluticasone[MESH]|Humans[MESH]|Pulmonary Disease, Chronic Obstructive/*drug therapy[MESH]|Salmeterol Xinafoate[MESH]|United Kingdom[MESH] |